Vor Biopharma Inc reports results for the quarter ended in September 30 - Earnings Summary

• Vor Biopharma Inc VOR.OQ reported a quarterly adjusted loss of 40 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -49 cents. The mean expectation of nine analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -44 cents to -36 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Vor Biopharma Inc's reported EPS for the quarter was a loss of 40 cents​.

• The company reported a quarterly loss of $27.56 million.

• Vor Biopharma Inc shares had risen by 22.9% this quarter and lost 61.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Vor Biopharma Inc is $12.00

This summary was machine generated from LSEG data November 8 at 02:25 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)